Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04329728 · ClinicalTrials.gov registry record · Phase 1
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
A Phase 1 study of Lymphoid Malignancies, sponsored by AVM Biotechnology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 11
- Study locations
NCT04329728: Recruiting Phase 1 study of Lymphoid Malignancies, sponsored by AVM Biotechnology.
NCT04329728 is a Phase 1 study of Lymphoid Malignancies that is actively recruiting participants, run by AVM Biotechnology. The registered enrollment target is 144 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (140% higher). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04329728, a Phase 1 study of Lymphoid Malignancies, is actively recruiting participants, sponsored by AVM Biotechnology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Primary Outcome
The primary endpoint for the Phase 1 portion of the study is the incidence of Adverse events (AEs), including DLTs.
Conditions Studied
Interventions
- DRUG AVM0703
Study Locations (11)
California
- City of Hope - Duarte
- Los Angeles Cancer Network - Los Angeles
- UCLA Medical Center of Hematology/Oncology - Los Angeles
- Innovative Clinical Research Institute - Whittier
Florida
- ASCLEPES Research Centers - Weeki Wachee
Illinois
- University of Illinois at Chicago Cancer Center - Chicago
Kentucky
- Norton Cancer Institute - Louisville
Nebraska
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Omaha
Ohio
- Gabrail Cancer Center Research, - Canton
Tennessee
- Baptist Clinical Research Institute - Memphis
Texas
- University of Texas(UT) Southwestern-Children's Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2020-11-06 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 1 |
What NCT04329728 shows while recruiting
NCT04329728 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (140% higher).
The record links to 1 condition, with Lymphoid Malignancies appearing as the primary indexed condition, and to 1 intervention - of which AVM0703 is the first listed.
NCT04329728 lists 11 locations in 8 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT04329728 about?
NCT04329728 is a clinical study titled "The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies". This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
What is the current status of trial NCT04329728?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2020-11-06. Estimated completion is 2026-12-01.
What conditions does trial NCT04329728 study?
This clinical trial studies the following conditions: Lymphoid Malignancies.
What interventions are being tested in trial NCT04329728?
The interventions under investigation include: AVM0703 (DRUG).
Who is sponsoring clinical trial NCT04329728?
This trial is sponsored by AVM Biotechnology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04329728 being conducted?
This trial has 11 study locations across California, Florida, Illinois, Kentucky, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04329728's enrollment target sits among peer trials
144 395th of 2000 higher than 1,600 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI